International Immunology Advance Access published online on October 31, 2006
International Immunology, doi:10.1093/intimm/dxl112
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pharmacology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany
* To whom correspondence should be addressed. IL-12 and IL-18 are mediators involved in the onset and progression of the autoimmune disease developing in MRL/Mp-Tnfrsf6lpr (lpr) mice, which display symptoms similar to the human systemic lupus erythematosus (SLE). The pathology is characterized by progressive lymphadenopathy and auto-antibody-mediated multiple organ failure, e.g. glomerulonephritis, or pneumonitis and a concomitant increase in serum levels for IFN
Received May 6, 2005
Accepted September 25, 2006
Article
Injection of IL-12- and IL-18-encoding plasmids ameliorates the autoimmune pathology of MRL/Mp-Tnfrsf6lpr mice: synergistic effect on autoimmune symptoms
Detlef Neumann 1 *, Thomas Tschernig 2, Daniela Popa 2, Andreas Schmiedl 3, Guillermo Pérez de Lema 4, Klaus Resch 1, and Michael Uwe Martin 5
2 Department of Functional and Applied Anatomy, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany
3 Department of Microscopic Anatomy, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany
4 Ludwig-Maximilians-University, Medizinische Poliklinik, D-80336 Munich, Germany
5 Department of Pharmacology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; Present address: Institute of Immunology, Justus-Liebig-University, Winchesterstrasse 2, D-35394 Giessen, Germany
Detlef Neumann, E-mail: neumann.detlef{at}mh-hannover.de
![]()
Abstract
and tumor necrosis factor-
(TNF
). In this study, we intramuscularly injected lpr mice with plasmids encoding IL-12 and IL-18, either alone or in combination, in order to affect the development of the autoimmune disease. Five biweekly injections of the combined plasmids starting at 4-5 weeks of age diminished serum levels of TNF
and reduced the ability of lymphocytes from treated mice to produce IFN
in vitro. Injection of both plasmids synergistically attenuated the development of autoimmune syndromes, lymphoproliferation in secondary lymphoid organs, proteinuria and kidney damage and pneumonitis. We conclude that IL-12 and IL-18 synergistically affect the pathogenesis of the Th1-dependent autoimmune syndrome of lpr mice and that approaches that target both IL-12 and IL-18 may be a therapeutic option in the treatment of autoimmune SLE.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. Sanchez, R. J. Palomino-Morales, N. Ortego-Centeno, J. Jimenez-Alonso, M. A. Gonzalez-Gay, M. A. Lopez-Nevot, J. Sanchez-Roman, E. de Ramon, M. F. Gonzalez-Escribano, B. A. Pons-Estel, et al. Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus Hum. Mol. Genet., October 1, 2009; 18(19): 3739 - 3748. [Abstract] [Full Text] [PDF] |
||||
